EUVIMEDEUVIMED entdecken
Open Access

Incidence, Prevalence, and Survival of Prostate Cancer in the UK

Eng Hooi Tan, Edward Burn, Nicola L Barclay, Antonella Delmestri, Wai Yi Man, Asieh Golozar, Àlvar Roselló Serrano, Talita Duarte-Salles, Philip Cornford, Daniel Prieto Alhambra, Danielle Newby, OPTIMA Consortium

JAMA Network Open · 19.09.2024 · 7 (9) · e2434622

DOI: 10.1001/jamanetworkopen.2024.34622 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 19.09.2024. Verfasst von Eng Hooi Tan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Unit…. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Incidence, prevalence, and survival are pertinent measures to inform the management and provision of prostate cancer care.

Objective

To calculate the incidence, prevalence, and survival rates for prostate cancer in the UK from 2000 to 2021. Design, Setting, and Participants This population-based cohort study uses routinely collected primary care data from the UK. Male patients aged 18 years or older with at least 1 year of history registered in Clinical Practice Research Datalink (CPRD) GOLD or Aurum were included. Data were analyzed from January 2023 to March 2024. Main Outcomes and Measures Prostate cancer incidence rates (IR), period prevalence (PP), and 1-, 5-, and 10-year survival after diagnosis between 2000 and 2021, stratified by age and calendar years.

Results

This study included 64 925 and 133 200 patients with prostate cancer in CPRD GOLD and Aurum, respectively, with a median age of 72 (65-78) years. The overall IR of prostate cancer was 151.7 (95% CI, 150.6 to 152.9) per 100 000 person-years in GOLD to 153.1 (95% CI, 152.3 to 153.9) per 100 000 person-years for Aurum and increased with age. The incidence of prostate cancer increased from 109 per 100 000 person-years in 2000 to 159 per 100 000 person-years in 2021. Peaks of incidence occurred in 2004 and 2018, before a decline in 2020. PP increased 3.5 times over the study period for both databases, from 0.4% in 2000 to 1.4% in 2021. IR and PP were highest in those aged 80 to 89 years. Median (95% CI) survival was similar in both databases (GOLD: 10.9 [95% CI, 10.7-11.1] years and Aurum: 11.1 [95% CI, 11.0-11.2] years). Survival at 1, 5, and 10 years after diagnosis were 93.4% (95% CI, 93.2%-93.6%), 71.8% (95% CI, 71.4%-72.2%), 53.2% (95% CI, 52.6%-53.7%) in GOLD and 93.9% (95% CI, 93.7%-94.0%), 72.7% (95% CI, 72.5%-73.0%), 53.7% (95% CI, 53.3%-54.1%) in AURUM, respectively. Survival increased over time: 1-year survival was 94.8% (95% CI, 94.5%-95.2%) in those diagnosed between 2015 to 2019 compared with 90.8% (95% CI, 90.2%-91.3%) from 2000 to 2004; 5-year survival improved from 65.3% (95% CI, 64.4%-66.3%) from 2000 to 2004 to 75.3% (95% CI, 74.4%-76.3%) in 2015 to 2019. Conclusions and Relevance In this population-based cohort study, incidence and prevalence increased with older age, with high survival rates reflecting a high burden of disease, particularly in the management of cancer survivorship in an aging population. Health care systems should consider this when managing the increasing numbers of people with prevalent prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleAgedIncidenceUnited KingdomPrevalenceMiddle AgedCohort StudiesSurvival RateAged, 80 and overAdult

Autor:innen und Institutionen

  • Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
  • Odysseus Data Service, Cambridge, Massachusetts.
  • Observational Health Data Sciences and Informatics Center at the Roux Institute, Northeastern University, Boston, Massachusetts.
  • Institut Català d'Oncologia, Hospital Universitari Dr Josep Trueta, Girona, Catalonia, Spain.
  • Fundació Institut Universitari per a la recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Barcelona, Spain.
  • Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, the Netherlands.

Zitieren

APA

Tan, E. H., Burn, E., Barclay, N. L., Delmestri, A., Man, W. Y., Golozar, A., Serrano, À. R., Duarte-Salles, T., Cornford, P., Prieto Alhambra, D., Newby, D., & OPTIMA Consortium (2024). Incidence, Prevalence, and Survival of Prostate Cancer in the UK. JAMA Network Open, 7(9), e2434622. https://doi.org/10.1001/jamanetworkopen.2024.34622

Vancouver

Tan EH, Burn E, Barclay NL, Delmestri A, Man WY, Golozar A, et al. Incidence, Prevalence, and Survival of Prostate Cancer in the UK. JAMA Network Open. 2024;7(9):e2434622. doi:10.1001/jamanetworkopen.2024.34622

BibTeX
@article{Tan2024,
  author = {Tan, Eng Hooi and Burn, Edward and Barclay, Nicola L and Delmestri, Antonella and Man, Wai Yi and Golozar, Asieh and Serrano, Àlvar Roselló and Duarte-Salles, Talita and Cornford, Philip and Prieto Alhambra, Daniel and Newby, Danielle and OPTIMA Consortium, OPTIMA Consortium},
  title = {Incidence, Prevalence, and Survival of Prostate Cancer in the UK},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {9},
  pages = {e2434622},
  doi = {10.1001/jamanetworkopen.2024.34622}
}
Kostenlos starten →